Ryanodine receptor 2 mutation: Not only catecholaminergic polymorphic ventricular tachycardia but also epileptiform discharges in electroencephalogram

Yingfang She, Yide Li, Hang Yu, Liemin Zhou

The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong Province, China

Abstract

Ca$^{2+}$ leak via ryanodine receptor type 2 (RyR2) can cause potentially fatal arrhythmias, and RyR2 mutations have been shown in the aetiology of catecholaminergic polymorphic ventricular tachycardia. We report the case of a patient with catecholaminergic polymorphic ventricular tachycardia resulting from a RYR2 mutation who had not only typical electroencephalogram changes, but also epileptiform discharges in electroencephalogram. We believe the changes were closely related to the RYR2 mutation.

Keywords: Catecholaminergic polymorphic ventricular tachycardia, ryanodine receptor, epilepsy, Purkinje cells, electroencephalogram

INTRODUCTION

Ryanodine receptors (RyR) are huge ion channels that release Ca$^{2+}$ from the endoplasmic reticulum (ER) and sarcoplasmic reticulum (SR). Three different isoforms (RyR1–RyR3) have been found.1 The RyR2 receptor is mainly expressed in cardiomyocytes, and the RYR2 mutation is well-established in the aetiology of catecholaminergic polymorphic ventricular tachycardia (CPVT).2 The RYR2 receptor is also expressed in the Purkinje cells of the cerebellum, the cerebral cortex, and the hippocampus.3 Patients with RYR2 mutations can develop Adams-Stokes syndrome, which can be easily misdiagnosed as epilepsy in the early stage. Many ion channels are also closely related to epilepsy, such as transient calcium channel, long-lasting calcium channel, voltage-gated sodium channels and potassium channels.4-7 In this case report, we examine whether RYR2 mutation might also be the aetiology of epilepsy.

CASE REPORT

A 9-year-old boy presented with recurrent episodes of unconsciousness for 4 years. Four years before, the boy had presented with palpitations, sweating and blurred vision after activities, followed by unconsciousness, and accompanied by faecal incontinence, upward deviation of the eyes and clonic jerks. After 1 minute, the patient regained consciousness. In the following 4 years, the patient experienced 6 similar attacks, all of which occurred after physical activity. There was no positive family history of sudden cardiac death, seizure, pregnancy loss or neonatal death.

Upon arrival, the patient was conscious, his vital signs were stable, and there were no positive findings confirmed by physical examination. Blood routine, blood electrolytes, blood glucose, blood gas analysis, myocardial troponin, thyroid function, liver function test, creatinine level, chest x-rays and magnetic resonance imaging of the brain were normal. Metabolic screening tests (plasma amino acids, urine organic acids, acylcarnitine profile, a very long-chain fatty acid profile) were also normal. Computed tomography angiography of the chest showed that there were 4 great arteries arising from the aorta’s upper convexity, namely the brachiocephalic, left common carotid, left vertebral artery and subclavian arteries. Holter electrocardiogram (ECG) showed that the rhythm of the patient was normal at rest, but frequent polymorphic ventricular premature beats and polymorphic ventricular tachycardia occurred during physical activity, with R on T present (Figure 1). Long-term video electroencephalogram (EEG) showed normal background activity associated with the alpha rhythm of 8 to 9 Hz in the posterior area, but right temporal area showed frequent epileptiform discharges during stage II, stage III and REM sleep (Figure 2).
Figure 1. (A) Sinus rhythm.

(B) The red rectangle indicates the non-sustained polymorphic ventricular tachycardia.

(C) Polymorphic ventricular premature beats and non-sustained polymorphic ventricular tachycardia on Holter monitoring were found when the patient was walking fast.

Genetic analysis was performed. At our institution, we analysed the entire exome of genetic disease. We found a heterozygous missense variant in the RYR2 gene (c.6577 G > T/p.V2193L) (Figure 3). The mutation was considered de novo because the genetic analyses of the parents were normal. According to current guidelines, the patient was diagnosed with CPVT and was given metoprolol tartrate sustained-release tablets orally. We believe the patient also experiences epilepsy; thus, he was also given levetiracetam orally. From the time of treatment until October 10, 2019, the patient had no further attacks at rest or with exercise.

This case report was published with the consent of the patient’s guardian.

DISCUSSION

RyRs, RyR1, RyR2, and RyR3, are a family of high conductance cation channels, which release Ca$^{2+}$ from intracellular stores (the ER and SR). RyR2 is expressed mainly in the SR of the mammalian heart. Our patient developed CPVT resulting from the RYR2 mutation.

Patients with RYR2 mutation and CPVT are reported to frequently initially present with seizures. However, in this case, the epilepsy was later thought to be misdiagnosed. Leenhardt
(A) Long-term video-electroencephalogram showed normal background activity associated with alpha rhythm of 8 to 9 Hz in the posterior area.

(B) The red arrows indicate electrodes recording from the right temporal area, which showed frequent epileptiform discharges during non-rapid eye movement II sleep.
(C) The red arrows indicate electrodes recording from the right temporal area, which showed frequent epileptiform discharges during non-rapid eye movement III sleep.

(D) The red arrows indicate electrodes recording from the right temporal area, which showed frequent epileptiform discharges during rapid eye movement sleep.
followed 21 patients with CPVT for as many as 7 years, and he believes nearly half of these patients were initially misdiagnosed with epilepsy. Also, approximately 50% of RYR2 mutation carriers (6 of the 12 probands) in a large Dutch cohort presented with convulsive movements resulting from hypoperfusion of the brain. With antiepileptic drugs, syncope was also not relieved.14

In previous reports, epilepsy was not excluded as a diagnosis for some patients with RYR2 mutations.15,16 RyR2 is also expressed at high levels in the Purkinje cells of the cerebellum and cerebral cortex and may play a fundamental role in neuronal Ca\(^{2+}\) homeostasis.3,17 Does the RPR2 mutation cause abnormal electrical activity in the cerebral cortex, leading to seizures?

Aiba18 found that a leaky human RyR2 mutation, R176Q (RQ), alters the neurotransmitter release probability in mice and reported that rare episodes of spontaneous seizure were detected in RQ/+ mutant mice in vivo. Lehnart19 proposed that CPVT is a combined neurological and cardiac disease, in which leaky RyR2 channels in the brain trigger epilepsy, whereas the same leaky channels in the heart cause exercise-induced sudden cardiac arrest.

In a family with RYR2 mutation, a female presented with 3 unprovoked generalised seizures over 12 years. EEG showed epileptiform activity, whereas the ECG was normal at the same time. Her brother was diagnosed with CPVT and was found to be heterozygous for a novel mutation in the RYR2 gene. There were no family members with both EEG and ECG changes.20

Both polymorphic ventricular tachycardia in ECG and frequent epileptiform discharges in EEG were detected in the present case. Patients with ion channel disease may have focal epileptiform discharges or multifocal epileptiform discharges.21 The epileptiform activity of our patient appeared in a periodic pattern during wakefulness and sleep and may be the result of genetic factors. Metabolic, structural, immune, infection and other factors were ruled out.

The patient underwent a genetic analysis of the whole exome. Based on the sequencing analysis, a heterozygous mutant in the RYR2 gene at chromosome 1q43, c.6577 G > T/p.V2193L was identified, which is highly conserved across all species (Table 1). The residue was located at the cytoplasmic loop of the RyR2 (Figure 4),

Table 1: The methionine at position 2193 is conserved in RyR2 from humans, mice, rhesus monkeys, dogs, elephants, zebrafish and lampreys

<table>
<thead>
<tr>
<th>site</th>
<th>species</th>
<th>2190</th>
<th>2191</th>
<th>2192</th>
<th>2193</th>
<th>2194</th>
<th>2195</th>
<th>2196</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>P</td>
<td>K</td>
<td>M</td>
<td>V</td>
<td>A</td>
<td>N</td>
<td>N</td>
<td>C</td>
</tr>
<tr>
<td>Rhesus</td>
<td>P</td>
<td>K</td>
<td>M</td>
<td>V</td>
<td>A</td>
<td>N</td>
<td>N</td>
<td>C</td>
</tr>
<tr>
<td>Mouse</td>
<td>P</td>
<td>K</td>
<td>M</td>
<td>V</td>
<td>A</td>
<td>N</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Dog</td>
<td>P</td>
<td>K</td>
<td>M</td>
<td>V</td>
<td>A</td>
<td>N</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Elephant</td>
<td>P</td>
<td>K</td>
<td>M</td>
<td>V</td>
<td>A</td>
<td>N</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Chicken</td>
<td>P</td>
<td>K</td>
<td>M</td>
<td>V</td>
<td>A</td>
<td>N</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Zebrafish</td>
<td>P</td>
<td>K</td>
<td>M</td>
<td>V</td>
<td>A</td>
<td>N</td>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Lampray</td>
<td>P</td>
<td>K</td>
<td>M</td>
<td>V</td>
<td>A</td>
<td>N</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>
Figure 4. The residue alteration in RYR2 gene was located at the cytoplasmic loop. The red bold square indicates RYR p.V2193L which located at the cytoplasmic loop of the RyR2.

Figure 5. (A) The tertiary structure of the ryr2 protein. The mutation site is identified in red.
and it was not located at the hot-spot of the previously reported concentrated mutation clusters (Figure 5). This mutation is close to the central domain cluster (2246–2534), which determines whether RyR is in an open or closed state. A mutation in the N-terminus construct (p.S2246L) may cause CPVT. In addition, RyR2 has been found to have 3 well-defined phosphorylation sites (i.e., S2030, S2809, and S2815), and may have other sites.

This mutation site has not been reported previously, and further functional tests are lacking. We used computer software to further analyse the pathogenicity of the mutation at this site. Using polymorphism phenotyping v2, the mutation was predicted to be probably damaging with a score of 1. Therefore, we hypothesised that the mutation leads to a change in the important physiological conformation of RYR2 protein and results in channel dysfunction, which further leads to typical ECG and EEG changes.

CPVT is a genetic disease associated with pathogenic variants of calcium handling genes. Moreover, as the novel variant (c.6577G>T) of RYR2 could result in the alteration of encoded amino acid sequence, we hypothesised that physiologically important altered conformation of RYR2 protein would render the channel more sensitive to stimuli, resulting in channel dysfunction. This new mutant might shed some light on the understanding of RYR2 function and its roles in CPVT if it is further confirmed in more clinical samples and unravelled through structure-function analysis.

**DISCLOSURE**

Conflict of interest: None

**REFERENCES**

8. Pflaumer A, Davis AM. Guidelines for the diagnosis


